We investigated the feasibility and efficacy of a fludarabine-based dose-reduced conditioning regimen followed by stem cell transplantation from related (n ‫؍‬ 5) or unrelated HLA-matched donors (n ‫؍‬ 7) in 12 patients with high risk MDS, who were not eligible for a standard myeloablative conditioning regimen. The conditioning regimen consisted of fludarabine 30 mg/m 2 daily for 6 days, busulfan 4 mg/kg daily for 2 days and anti-thymocyte globulin (ATG, rabbit) 10 mg/kg daily for 4 days in 11 patients, while one patient received fludarabine, ATG, cyclophosphamide and thiotepa. Graftversus-host disease prophylaxis consisted of cyclosporine and a short course of methotrexate. The median age of the patients was 53 years (range 37-59). The median percentage of blasts in bone marrow aspirate at transplantation was 15% (range Ͻ5% to 35%). Diagnosis at transplant was RA (n ‫؍‬ 1), RAEB (n ‫؍‬ 5), RAEB-T (n ‫؍‬ 5) and sAML (n ‫؍‬ 1). A complex karyotype including monosomy 7 was noted in five patients. The reasons for using a dose-reduced conditioning regimen were prior autologous/syngeneic BMT (n ‫؍‬ 4), active fungal infection (n ‫؍‬ 2) or age/reduced performance status (n ‫؍‬ 6). Engraftment was observed in all patients with complete donor chimerism. The incidence of acute GVHD (grade II-IV) was 33%. Eight patients died during follow-up due to relapse (n ‫؍‬ 4), liver toxicity (n ‫؍‬ 2), aspergillus (n ‫؍‬ 1) or aGVHD grade IV (n ‫؍‬ 1). After a median follow-up of 19 months, the 2-year estimated diseasefree survival is 12% (95% CI: 2-23%) and the overall survival is 26% (95% CI: 4-52%). Fludarabine dosereduced conditioning prior to allogeneic stem cell transplantation in high risk MDS patients, who were not eligible for standard transplantation, resulted in stable engraftment with complete chimerism, but the toxicity and relapse rate were considerable. Bone Marrow Transplantation (2001) 28, 643-647. Keywords: MDS; non-myeloablative conditioning; antithymocyte globulin; allogeneic stem cell transplantation
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The median survival of patients with RAEB or RAEB-T is less than 12 months. 1 Furthermore, an abnormal karyotype is also an adverse prognostic factor. 2 The curative therapeutic option for MDS is allogeneic stem cell transplantation from a related or unrelated donor, resulting in a disease-free survival probability of 36% for HLA-identical siblings and of 25% for matched unrelated donor stem cell transplants. 3 However, due to the high morbidity and mortality only younger patients are eligible for standard conditioning followed by allogeneic transplantation. Recently, so-called non-myeloablative conditioning regimens have offered new possibilities for patients who were not eligible for standard transplantation because of age, performance status or prior transplantation. [4] [5] [6] [7] We herein report the feasibility and efficacy of a fludarabine-based dose-reduced conditioning regimen, according to the Slavin scheme, followed by stem cell transplantation from related or unrelated donors in 12 patients with advanced MDS or sAML, who were not eligible for a standard myeloablative conditioning regimen.
Materials and methods

Patient characteristics
The study group consisted of 12 consecutive patients who had related (n ϭ 5) or unrelated (n ϭ 7) donor stem cell transplants between 1998 and December 2000 at the University Hospital Eppendorf in Hamburg and the ChariteVirchow Hospital, University Berlin/Germany. Written informed consent was obtained from each patient, and the study was approved by the local ethics committee. Patient characteristics are shown in Table 1 . Mean recipient age was 53 years (range, 37-59). There were six males and six females. Median follow-up of the surviving patients was 19 months (range, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Diagnoses at transplantation were RA (n ϭ 1), RAEB (n ϭ 5), RAEB-T (n ϭ 5) and sAML HLA-A and -B antigens were typed by serologic methods and HLA-DRB1 alleles with sequence-specific oligonucleotide probes. Donors were required to match the recipients for the serologically defined HLA-A and -B antigens, as well as the HLA-DRB1 alleles. All patients were completely matched for HLA-A, -B and -DRB1.
Transplant-preparative regimen and GVHD prophylaxis
Eleven patients were conditioned with fludarabine 30 mg/m 2 /day on days Ϫ10 to Ϫ5; oral busulfan 4 mg/kg/day on days Ϫ6 and Ϫ5, and i.v. rabbit anti-thymocyte globuline (ATG, Fresenius AG, Munich, Germany) 10 mg/kg/day on days Ϫ4 to Ϫ1. One patient received fludarabine, ATG and cyclophosphamide (6000 mg/kg) and thiotepa (300 mg/m 2 ) because of prior autologous transplantation with a busulfan-containing conditioning regimen. Phenytoin was given to prevent busulfan-induced seizures until 2 days after stopping busulfan.
On day 0, patients received an unmanipulated stem cell graft either from G-CSF-mobilised peripheral blood stem cells (PBSC) (n ϭ 4) or bone marrow (n ϭ 8). All patients received granulocyte-stimulating factor (G-CSF, 5 g/kg) intravenously beginning on day 1 or day 5 and continued until the absolute granulocyte count was Ͼ1.0/nl for 3 consecutive days.
GVHD prophylaxis consisted of cyclosporine A (3 mg/kg daily, given from day Ϫ1 to day 100 post transplantation). The dose of cyclosporine A was adjusted to serum levels of 200-300 ng/ml. Cyclosporine A was tapered from day 75 and discontinued at day 100. Methotrexate (10 mg/m 2 ) was given on days 1, 3 and 6 post transplantation. Standard criteria were used to diagnose and grade acute and chronic GVHD. 8 Acute GVHD was treated with high-dose steroid, and extensive chronic GVHD with cyclosporine A and steroids. Chronic GVHD was evaluated in patients who survived at least 80 days with sustained engraftment.
Regimen-related toxicity was graded using the Bearman system. 9 The maximum score for each organ system was recorded. Attempts were made to exclude toxicities due to GVHD from therapy-related toxicity.
Chimerism was assessed by various numbers of tandem repeats (VNTR) polymerase chain reaction (PCR).
Statistical methods
Disease-free, relapse-free and overall survival were calculated from start of therapy to the respective event. Death from whatever cause was counted as an event in cases of disease-free survival. All time-to-event curves were estimated according to the method of Kaplan and Meier. 10 
Results
Engraftment and chimerism
All patients engrafted and no graft failures were observed. The median number of transplanted CD34 ϩ cells was 2.9 ϫ 10 6 per kg (range, 1.7-6.2). The median time to reach the leukocyte count 1.0 ϫ 10 9 /l was 17 days (range, 11-27). Nine patients were evaluable for platelet engraftment and a platelet count Ͼ20 ϫ 10 9 /l with transfusion independence was reached after a median of 22 days (range, 11-34). All patients had nearly 100% donor cells as confirmed by VNTR-PCR techniques (Table 2) .
GVHD
Four patients had grade II-IV acute GvHD (33%), while eight patients (67%) experienced no GVHD. Severe grade IV GVHD developed in one patient, who died from acute GVHD. One patient developed acute GVHD after discontinuation of cyclosporine at day 105. Chronic GVHD was seen in three patients; two patients had limited disease and one patient experienced extensive GVHD and required further immunosuppression consisting of prednisone or cyclosporine A.
Toxicity and transplant-related mortality
The major toxicity was related to the liver. The median serum bilirubin level of the patients was 4.3 mg/dl (range, 1.4-31). In most cases a transjugular liver biopsy was undertaken, confirming the toxicity without any histological signs of GVHD or CMV infection. According to the Seattle criteria, three patients experienced mild and one patient moderate veno-occlusive disease (VOD). According to the Bearman score mucositis grade I and II developed in four and seven patients, respectively (Table 3) . Severe mucositis grade III, requiring mechanical ventilation was seen in one patient. There were four deaths (33%) due to treatment. The causes of treatment-related deaths were liver toxicity (n ϭ 2), aspergillus infection (n ϭ 1), and acute GVHD (n ϭ 1). I  0  2  I  0  I  3  I I  I  0  4  III  IV  0  5  I I  I I  0  6  I I  I  0  7  I  II  I  8  I I  0  0  9  I  IV  II  10  I  I  0  11  I  0  0  12  I  II  0   a Grade I ϭ reversible without treatment; grade II ϭ requires treatment but is not life threatening; grade III ϭ requires life support; grade IV ϭ fatal.
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Overall and disease-free survival
After a median follow-up of 19 months, the 2-year estimated disease-free survival is 12% (95% CI: 2-23%) and the overall survival is 26% (95% CI: 4-52%) (Figures 1  and 2 ). 
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Discussion
Patients with advanced MDS classified as RAEB or RAEB-T receiving conventional therapy have a median overall survival of only 5 to 10 months. Allogeneic stem cell transplantation is probably the only curative approach for patients with MDS. In a retrospective EBMT study, the estimated 3 years disease-free survival was 36% for patients with a related donor and 25% for patients with a matched unrelated donor. The treatment-related mortality for a conventional allograft is 37% for patients with RA and 52% for patients with RAEB or RAEB-T. 3 Because of the high mortality due to the intensive treatment, only young patients with an HLA-compatible related or unrelated donor were eligible for an allotransplantation. Since it became apparent that the curative potential of allogeneic stem cell transplantation is partly due to an immunemediated graft-versus-tumor effect new less toxic intensity reduced conditioning regimens have been developed. Such so-called non-myeloablative regimens were either fludarabine or low-dose TBI based. [4] [5] [6] Slavin et al 4 investigated a fludarabine-based regimen in 26 patients with a variety of hematologic diseases including four patients with nonmalignant disease. In this study fludarabine (30 mg/m 2 for 5 days), busulfan (4 mg/kg for 2 days) and anti-thymocyte globulin (ATG, rabbit, 10 mg/kg for 4 days) were used as conditioning in HLA-identical sibling transplantation. Minimal mucositis and no pulmonary toxicity was observed. However, 13 patients experienced mild or severe veno-occlusive disease of the liver. Severe acute GVHD (grade III and IV) occurred in six patients and four of them died of GVHD early after discontinuation of cyclosporine. In our study we investigated the same regimen in a cohort of high-risk MDS or sAML patients who were not eligible for a myeloablative conventional allotransplantation because of age, prior autologous transplant or active fungal infection. Because of the high incidence of severe aGVHD reported in the Slavin trial, we added a short course of methotrexate on days ϩ1, ϩ3, and ϩ6 and continued cyclosporine until day 100. The rate of GVHD grade II-IV was 33% in our trial; however, one patient died of GVHD grade IV. The toxicity was considerable, with grade II mucositis in 58% of the patients, and one patient experienced grade III mucositis requiring mechanical ventilation. The major problem however, was liver toxicity with a median maximum serum bilirubin of 4.3 mg/dl and two liver toxicity-related deaths. The observed higher toxicity in our trial compared with the study reported by Slavin et al might be due to the more extensive pretreatment including a prior transplant in four patients. Another reason for higher toxicity, but lower GVHD could be the incorporation of short course methotrexate after stem cell transplantation, which was not done in the Jerusalem trial. Thirty-three percent relapses were observed and all of them died. This is in accordance with the relapse rate of a myeloablative regimen 3 and may be also due to the prominent risk factors of the patients included such as complex chromosomal abnormalities and a high percentage of blasts at time of transplantation. No graft failures were observed in our study and all recipients achieved complete donor chimerism. Prompt establishment of complete donor hematopoesis appears to be necessary to achieve a maximum graft-versus-tumor effect and the benefit of this treatment modality. 7 In contrast to the Slavin trial, matched unrelated donors were also included and the stem cell source was bone marrow in eight patients. It is of note that all patients with unrelated donors and all patients with bone marrow as the stem cell source showed stable engraftment. Few MDS patients have been reported who underwent dose-reduced allografting. Recently, different non-myeloablative regimens followed by allogeneic stem cell transplantation in 53 patients with MDS have been analyzed in a retrospective study of the EBMT and a treatment-related mortality of 48% and a relapse rate of 33% have been reported. 11 Taking this EBMT data and our results together, the incidence of treatment-related mortality after dose-reduced conditioning does not differ significantly from the TRM after myeloablative allografting in MDS patients. However, one has to keep in mind that all the patients transplanted with a dose-reduced conditioning regimen were ineligible for a conventional myeloablative allograft. Four of our patients had received prior autologous or syngeneic transplants. The treatmentrelated mortality of a second myeloablative transplantation is up to 50% 12, 13 and recently the Jerusalem group reported a 50% disease-free survival for a second non-myeloablative regimen followed by allotransplantation.
14 Because of the short follow-up it can only be concluded that a dosereduced conditioning followed by allografting in patients with advanced MDS is a feasible approach with considerable toxicity, but the curative potential needs to be determined.
